Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results

Puma Biotechnology (NASDAQ:PBYI) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05, FiscalAI reports. The firm had revenue of $75.50 million during the quarter, compared to the consensus estimate of $68.60 million. Puma Biotechnology had a return on equity of 36.17% and a net margin of 17.45%.

Here are the key takeaways from Puma Biotechnology’s conference call:

• Q4 2025 results showed continued commercial momentum with total revenue of $75.5M and product net revenue of $59.9M, and management guides full‑year 2026 net NERLYNX product revenue of $194M–$198M and GAAP net income of $10M–$13M.
• Management expects higher gross‑to‑net reductions (FY2026 ~27.5%–28.5%; Q1 ~29.5%–30.5%) and is guiding a Q1 2026 net loss of $8M–$10M, which could pressure near‑term margins and results.
• Clinical programs advanced — the ALISCA‑Breast1 trial reached and exceeded its 150‑patient target ahead of schedule (164 enrolled) with interim data expected in Q2 2026, and ALISCA‑Lung1 is escalating doses (60mg, planned 70mg) with an interim readout also expected in Q2 2026, representing potential near‑term catalysts.
• Commercial demand trends were healthy with ex‑factory bottle sales up ~12% q/q to 3,298 bottles, SD (specialty distributor) channel growth strong (SD +17% q/q, +46% y/y), and recent international launches (Algeria, Thailand) expanding reach.
• Puma expects R&D to rise ~30%–35% and SG&A to rise 3%–5% in 2026; cash and securities were ~$97.5M at year‑end with outstanding debt ≈$22M, so higher spend could strain liquidity if commercial trends weaken.

Puma Biotechnology Stock Performance

PBYI stock traded down $0.08 during trading on Thursday, hitting $7.60. 491,764 shares of the company traded hands, compared to its average volume of 384,731. The company has a 50-day moving average of $6.49 and a 200-day moving average of $5.58. Puma Biotechnology has a 1 year low of $2.58 and a 1 year high of $7.68. The firm has a market capitalization of $382.96 million, a PE ratio of 10.27 and a beta of 1.22.

Insider Activity at Puma Biotechnology

In related news, insider Douglas M. Hunt sold 5,014 shares of Puma Biotechnology stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total value of $29,482.32. Following the transaction, the insider directly owned 155,907 shares of the company’s stock, valued at $916,733.16. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Alan H. Auerbach sold 18,012 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $105,910.56. Following the sale, the chief executive officer directly owned 7,145,951 shares of the company’s stock, valued at $42,018,191.88. The trade was a 0.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 43,937 shares of company stock valued at $257,513 in the last quarter. Corporate insiders own 23.30% of the company’s stock.

Hedge Funds Weigh In On Puma Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in shares of Puma Biotechnology in the second quarter worth $135,000. Brandywine Global Investment Management LLC purchased a new position in shares of Puma Biotechnology in the 4th quarter worth about $130,000. Heron Bay Capital Management bought a new position in Puma Biotechnology in the 4th quarter worth about $119,000. Squarepoint Ops LLC boosted its stake in Puma Biotechnology by 19.9% in the 3rd quarter. Squarepoint Ops LLC now owns 21,334 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 3,540 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Puma Biotechnology during the 4th quarter valued at about $112,000. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Puma Biotechnology in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.